| UNH |
Report |
Adjusted EPS |
BEAT |
pred ~$4.96 vs. cons $4.84 |
MEDIUM |
| UNH |
Report |
Revenue |
IN-LINE |
pred ~$111.2B vs. cons $110.7B |
MEDIUM |
| UNH |
Report |
Medical care ratio |
IN-LINE |
pred ~88.1% vs. cons 88.5% |
MEDIUM |
| UNH |
Guide |
Adjusted EPS guidance |
BETTER |
guide ~$18.75 vs. cons $18.32 (FY2026) |
MEDIUM |
| UNH |
Guide |
Medical care ratio guidance |
UNCHANGED |
guide ~88.5% vs. cons 88.5% (FY2026) |
MEDIUM |
| UNH |
Guide |
Implied adjusted EPS |
BETTER |
guide ~$6.57 vs. cons $6.25 (H2 2026) |
LOW |
| UNH |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.2% |
— |
MEDIUM |
| UNH |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
A ~$0.43 FY2026 guide advantage and implied H2 adjusted EPS of ~$6.57 versus ~$6.25 consensus should drive positive revisions beyond the quarterly beat, supporting follow-through rather than a fade. |
MEDIUM |